Decentralized Liquid Biopsy on Chip for Equitable Cancer Care

Source: Oncodaily - Oncology News, Insights, Stories, by Aharon Tsaturyan (August 9, 2025). AI-generated summary by biochip.com, published June 17, 2026. Not independently reviewed.

Portable liquid-biopsy platforms could move parts of cancer testing from centralized laboratories to clinics, community settings, and eventually homes, but they still need broad validation before routine use. Stefano Cinti's Uninanobiosensors laboratory at the University of Naples Federico II is developing paper-based and electrochemical devices aimed at detecting cancer-linked molecules in small fluid samples. The approach centers on liquid biopsy, which looks for tumor-related material in blood and other accessible fluids rather than requiring a tissue sample. In particular, the group is targeting microRNA signatures, exosomes, and protein biomarkers that could help clinicians assess cancer risk, disease behavior, or treatment response. Its reported paper-based platforms can measure miRNA-21 and miRNA-105, two biomarkers associated with metastasis, in complex biological fluids. The larger goal is decentralized, lower-cost testing that reduces dependence on cold storage, specialized equipment, and large sample volumes. That goal matters most in low- and middle-income countries, where infrastructure barriers can delay diagnosis until cancer has reached an advanced stage. Still, a promising sensor is not yet a healthcare service: standardization, testing across diverse patient cohorts, and integration into clinical systems remain central challenges.

What liquid biopsy measures

A conventional tissue biopsy takes a piece of a tumor for laboratory analysis. Liquid biopsy takes a different route, more like examining traces left behind rather than entering the building itself. It analyzes tumor-derived material released into bodily fluids, including circulating tumor cells, cell-free DNA, extracellular vesicles, proteins, and microRNAs.

MicroRNAs, often shortened to miRNAs, are very small RNA molecules that help regulate which genes cells use. Certain miRNA patterns can be associated with particular tumor subtypes or disease processes. Cinti highlights their stability and tumor-subtype specificity as features that make them attractive targets for point-of-care cancer testing.

Putting the test on paper

The University of Naples Federico II team combines electrochemical sensing with paper-based analytical devices, often called PADs. A paper-based diagnostic works much like a highly engineered version of a test strip: a liquid sample moves through a patterned paper surface, where chemical reactions can generate a readable signal. The format can reduce the amount of equipment, sample, and storage infrastructure needed for an assay.

Electrochemical sensors turn a biological interaction into an electrical measurement. In this case, nanomaterials are used to enhance the sensor's response to target molecules. The intended result is a portable test that can detect several biomarkers at once, known as multiplexing, instead of requiring separate tests for each molecular target.

Targets linked to metastasis

Among the laboratory's reported developments are multiplexed paper platforms for miRNA-21 and miRNA-105. These microRNAs are linked to metastasis, the process in which cancer spreads from its original location to other parts of the body. The devices are designed to detect the targets with high sensitivity even when the sample contains the many interfering substances found in real biological fluids.

The team frames this work around therapeutic miRNA signatures, exosomes, and protein biomarkers. Exosomes are tiny membrane-bound particles released by cells that can carry molecular cargo, including RNA and proteins. Measuring several classes of tumor-related material could potentially give clinicians a richer picture than relying on a single biomarker, although the clinical role of any combined test must be established through validation.

Why decentralization is the central idea

Centralized diagnostic laboratories can provide sophisticated testing, but they often depend on trained personnel, specialized instruments, controlled sample transport, and cold-chain storage. Those requirements can be difficult to meet in resource-limited settings or for patients who live far from major medical centers. Cinti's group aims to reduce those barriers with platforms that use smaller sample volumes and can provide visual results by eye or through a smartphone-based readout.

Point-of-care testing means performing an analysis near the patient rather than sending a sample away for processing. For liquid biopsy, that could shorten the interval between sample collection and a result that informs a clinical conversation. The potential applications discussed include early screening, therapy monitoring, clinical-trial stratification, and decentralized follow-up in at-home care models.

OncoCheck remains a conceptual model

The OncoCheck framework extends the device-level idea into a connected diagnostic model. It envisions combining liquid biopsy, point-of-care testing, and artificial intelligence analytics in a cloud-connected system. The concept is meant to support timely cancer screening and follow-up, particularly in settings where limited infrastructure contributes to delayed diagnosis.

That distinction is important. OncoCheck is presented as a conceptual framework, not as evidence of a fully deployed clinical system. Its proposed value depends on multiple pieces working together: reliable molecular detection, appropriate analysis of results, secure data connections, clinical oversight, and health systems able to act on a test result.

Why This Matters

Cancer care is often shaped by where a patient lives and what diagnostic resources are available nearby. The article notes that up to 70% of cancer cases in low- and middle-income countries are diagnosed at advanced stages because of infrastructure barriers. A small, lower-cost test that can be used outside a major laboratory could help narrow that gap if it delivers reliable results and fits local care pathways.

Liquid biopsy also offers an appealing practical advantage: it can draw information from accessible fluids such as blood, saliva, or urine. Repeated sampling may be easier than repeated tissue biopsies, which can be invasive and are not always feasible. But accessibility alone does not guarantee equity, since clinicians need validated thresholds, clear interpretation, and a plan for what happens after an abnormal result.

From promising platform to clinical use

Clinical studies such as BIOMILD and ANDROMEDA have helped support the broader idea that miRNA profiling can stratify cancer risk and predict treatment outcomes. The next steps for decentralized platforms are more specific: researchers must standardize how samples are collected and processed, test devices across diverse cohorts, and determine how results compare with established clinical methods. Policymakers, clinicians, and technology developers will also need to decide how these tests fit into existing cancer programs.

The direction is clear even if the route to implementation is demanding. Paper-based, electrochemical liquid-biopsy devices could make molecular testing more portable and practical, especially where laboratory capacity is scarce. Their eventual impact will depend on whether careful clinical validation can turn a compact sensor into a trusted part of cancer care.

Topics: Biosensors · Cancer · Diagnostics & precision medicine

Start here: Biosensors explained